$PHLT
Performant Healthcare Inc Stock $phlt

$phlt Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000155069522000033 Filed on May 10, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$25.68M	$27.08M	$31.58M
YoY Change	-21.8%	-13.72%	-21.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$20.87M	$20.30M	$20.09M
YoY Change	-5.61%	-15.75%	-23.22%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.158M	$1.102M	$1.305M
YoY Change	-22.8%	8.46%	13.48%
% of Gross Profit
Operating Expenses	$28.95M	$28.57M	$28.46M
YoY Change	-15.0%	-17.06%	-21.67%
Operating Profit	-$3.303M	-$1.487M
YoY Change	172.52%	-51.34%
Interest Expense	-$216.0K	$155.0K	-$5.447M
YoY Change	-110.16%	-88.48%	289.07%
% of Operating Profit
Other Income/Expense, Net	$382.0K		-$25.00K
YoY Change	-79.34%
Pretax Income	-$3.137M	-$1.642M	-$2.635M
YoY Change	110.68%	-62.7%	-214.07%
Income Tax	$32.00K	$31.00K	$1.000K
% Of Pretax Income
Net Earnings	-$3.169M	-$1.673M	-$2.636M
YoY Change	108.21%	-62.31%	-170.86%
Net Earnings / Revenue	-12.34%	-6.18%	-8.35%
Basic Earnings Per Share	-$0.04	-$0.02
Diluted Earnings Per Share	-$43.11K	-$0.02	-$38.03K
COMMON SHARES
Basic Shares Outstanding	73.14M shares	69.87M shares	69.14M shares
Diluted Shares Outstanding	73.50M shares	69.87M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.97M	$17.43M	$17.35M
YoY Change	60.55%	-9.21%	8.42%
Cash & Equivalents	$15.97M	$17.43M	$17.35M
Short-Term Investments
Other Short-Term Assets	$5.537M	$6.144M	$5.280M
YoY Change	-1.3%	4.14%	-13.44%
Inventory
Prepaid Expenses
Receivables	$29.08M	$19.84M	$20.81M
Other Receivables	$3.248M	$3.085M	$3.159M
Total Short-Term Assets	$53.84M	$55.37M	$54.71M
YoY Change	16.84%	0.46%	0.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.68M	$15.31M	$15.71M
YoY Change	10.48%	-8.51%	-10.22%
Goodwill		$47.40M	$47.40M
YoY Change		0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$969.0K	$965.0K	$963.0K
YoY Change	-1.62%	-3.5%	-12.93%
Total Long-Term Assets	$66.02M	$66.40M	$67.28M
YoY Change	-3.56%	-5.53%	-6.18%
TOTAL ASSETS
Total Short-Term Assets	$53.84M	$55.37M	$54.71M
Total Long-Term Assets	$66.02M	$66.40M	$67.28M
Total Assets	$119.9M	$121.8M	$122.0M
YoY Change	4.64%	-2.9%	-3.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$963.0K	$1.191M	$1.124M
YoY Change	13.83%	37.69%	176.17%
Accrued Expenses	$8.799M	$1.600M	$3.600M
YoY Change	174.97%	-55.56%	5.88%
Deferred Revenue		$800.0K	$600.0K
YoY Change		60.0%	-33.33%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$736.0K	$613.0K	$489.0K
YoY Change	-90.97%		-99.18%
Total Short-Term Liabilities	$14.06M	$13.27M	$17.51M
YoY Change	-47.8%	-83.65%	-77.33%
LONG-TERM LIABILITIES
Long-Term Debt	$18.63M	$18.86M	$19.08M
YoY Change	-52.52%	-68.29%
Other Long-Term Liabilities	$2.736M	$1.174M	$1.168M
YoY Change	-11.46%	-62.98%	-67.49%
Total Long-Term Liabilities	$21.37M	$20.03M	$20.25M
YoY Change	-49.52%	-68.02%	463.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.06M	$13.27M	$17.51M
Total Long-Term Liabilities	$21.37M	$20.03M	$20.25M
Total Liabilities	$35.43M	$34.91M	$39.56M
YoY Change	-50.56%	-59.99%	-53.04%
SHAREHOLDERS EQUITY
Retained Earnings		-$52.92M	-$51.25M
YoY Change		16.57%	25.12%
Common Stock		$139.8M	$133.7M
YoY Change		67.28%	61.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.43M	$86.87M	$82.42M
YoY Change
Total Liabilities & Shareholders Equity	$119.9M	$121.8M	$122.0M
YoY Change	4.64%	-2.9%	-3.36%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.169M	-$1.673M	-$2.636M
YoY Change	108.21%	-62.31%	-170.86%
Depreciation, Depletion And Amortization	$1.158M	$1.102M	$1.305M
YoY Change	-22.8%	8.46%	13.48%
Cash From Operating Activities	-$827.0K	-$4.651M	-$370.0K
YoY Change	-75.36%	-196.45%	-113.12%
INVESTING ACTIVITIES
Capital Expenditures	-$889.0K	$700.0K	-$721.0K
YoY Change	14.86%	-15.25%	-22.47%
Acquisitions
YoY Change
Other Investing Activities	$382.0K		-$25.00K
YoY Change	-84.12%
Cash From Investing Activities	-$507.0K	-$700.0K	-$746.0K
YoY Change	-131.07%	-15.25%	-19.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-125.0K	$5.436M	-32.86M
YoY Change	-98.34%	-713.54%	3677.01%
NET CHANGE
Cash From Operating Activities	-827.0K	-$4.651M	-370.0K
Cash From Investing Activities	-507.0K	-$700.0K	-746.0K
Cash From Financing Activities	-125.0K	$5.436M	-32.86M
Net Change In Cash	-1.459M	$85.00K	-33.98M
YoY Change	-84.22%	-97.27%	-3430.98%
FREE CASH FLOW
Cash From Operating Activities	-$827.0K	-$4.651M	-$370.0K
Capital Expenditures	-$889.0K	$700.0K	-$721.0K
Free Cash Flow	$62.00K	-$5.351M	$351.0K
YoY Change	-102.4%	-233.91%	-90.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001550695
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35628
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	PERFORMANT FINANCIAL CORPORATION
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0484934
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17347000	USD
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 North Canyons Parkway
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Livermore
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94551
CY2022Q1	dei	City Area Code CityAreaCode	(925)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	960-4800
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $.0001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	PFMT
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73143833	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17432000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	29000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19837000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20808000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8875000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8113000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3941000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3077000	USD
CY2022Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3085000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3159000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	55373000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	54707000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15306000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15708000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	47372000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	47372000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2760000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3235000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	965000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	963000	USD
CY2022Q1	us-gaap	Assets Assets	121776000	USD
CY2021Q4	us-gaap	Assets Assets	121985000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	13000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	11000	USD
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	612000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	489000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5935000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8476000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1191000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1124000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1762000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3732000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	773000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	634000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1471000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1190000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1528000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1862000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13272000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17507000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	392000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	416000	USD
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	18858000	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	19084000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1601000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1803000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1174000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1168000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	34905000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	39562000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73144000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73144000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69281000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69281000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	139783000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	133662000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52919000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51246000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	86871000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	82423000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121776000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121985000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27083000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31390000	USD
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	20439000	USD
CY2021Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	24090000	USD
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	8131000	USD
CY2021Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	10356000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	28570000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	34446000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1487000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3056000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	155000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1346000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1642000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4402000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1673000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4439000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69873000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54813000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69873000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54813000	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82423000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41980000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-23000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	558000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	649000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5563000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1673000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4439000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86871000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38167000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1673000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4439000	USD
CY2022Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	17000	USD
CY2021Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-636000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1102000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1016000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	475000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	507000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	558000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	649000	USD
CY2022Q1	pfmt	Interest Expense Debt Issuance Costs And Amortization InterestExpenseDebtIssuanceCostsAndAmortization	24000	USD
CY2021Q1	pfmt	Interest Expense Debt Issuance Costs And Amortization InterestExpenseDebtIssuanceCostsAndAmortization	369000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-971000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2616000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	762000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	283000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	864000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-117000	USD
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-74000	USD
CY2021Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-60000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-85000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2541000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	799000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	67000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	458000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1815000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-114000	USD
CY2022Q1	pfmt	Increase Decrease In Estimated Liability For Appeals And Disputes IncreaseDecreaseInEstimatedLiabilityForAppealsAndDisputes	281000	USD
CY2021Q1	pfmt	Increase Decrease In Estimated Liability For Appeals And Disputes IncreaseDecreaseInEstimatedLiabilityForAppealsAndDisputes	3359000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-536000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-591000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-422000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4651000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4822000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	700000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	826000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-700000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-826000	USD
CY2022Q1	pfmt	Repayments Of Long Term Notes Payable RepaymentsOfLongTermNotesPayable	125000	USD
CY2021Q1	pfmt	Repayments Of Long Term Notes Payable RepaymentsOfLongTermNotesPayable	863000	USD
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2000	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	23000	USD
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5563000	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5436000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-886000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	85000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3110000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19550000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18296000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19635000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21406000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17432000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19203000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19635000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21406000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	432000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	176000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	977000	USD
CY2022Q1	pfmt	Prepaid Expense And Other Assets Prepaid Software Licenses And Maintenance Agreements PrepaidExpenseAndOtherAssetsPrepaidSoftwareLicensesAndMaintenanceAgreements	2100000	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1200000	USD
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	600000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3100000	USD
CY2021Q4	pfmt	Prepaid Expense And Other Assets Prepaid Software Licenses And Maintenance Agreements PrepaidExpenseAndOtherAssetsPrepaidSoftwareLicensesAndMaintenanceAgreements	1400000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1100000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	600000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	47400000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	47400000	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	34200000	USD
CY2022Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	34200000	USD
CY2022Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingUnit
CY2021Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	600000	USD
CY2022Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	600000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1600000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74253000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15306000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15708000	USD
CY2022Q1	pfmt	Workers Compensation Liability Incurred WorkersCompensationLiabilityIncurred	100000	USD
CY2022Q1	pfmt	Accrued Third Party Fees Current AccruedThirdPartyFeesCurrent	100000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3600000	USD
CY2021Q4	pfmt	Workers Compensation Liability Incurred WorkersCompensationLiabilityIncurred	100000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90609000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	89961000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	75303000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	1100000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1000000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Revenue Recognition Interest RevenueRecognitionInterest	Revenues, Accounts Receivable, Contract Assets, Contract Liabilities, Estimated Liability for Appeals and Disputes The Company derives its revenues primarily from providing audit, recovery, and analytics services. Revenues are recognized upon completion of these services for its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. <div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts generally contain a single performance obligation, delivered over time as a series of services that are substantially the same and have the same pattern of transfer to the client, as the promise to transfer the individual services is not separately identifiable from other promises in the contracts and, therefore, not distinct.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts are composed primarily of variable consideration. Fees earned under the Company’s audit and recovery service contracts consist primarily of contingency fees based on a specified percentage of the amount the Company enables its clients to recover. The contingency fee percentage for a particular recovery depends on the type of recovery or claim facilitated.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally either applies the as-invoiced practical expedient where its right to consideration corresponds directly to its right to invoice its clients, or the variable consideration allocation exception where the variable consideration is attributable to one or more, but not all, of the services promised in a series of distinct services that form part of a single performance obligation. As such, the Company has elected the optional exemptions related to the as-invoiced practical expedient and the variable consideration allocation exception, whereby the disclosure of the amount of transaction price allocated to the remaining performance obligations is not required. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates variable consideration only if it can reasonably measure the progress toward complete satisfaction of the performance obligation using an output method based on reliable information, and recognizes such revenue over the performance period only if it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Any change made to the measure of progress toward complete satisfaction of the Company’s performance obligation is recorded as a change in estimate. The Company exercises judgment to estimate the amount of constraint on variable consideration based on the facts and circumstances of the relevant contract operations and the availability and reliability of data. The Company reviews the constraint on variable consideration at least quarterly. Although the Company believes the estimates made are reasonable and appropriate, different assumptions and estimates could materially impact the amount of variable consideration recognized.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts that contain a refund right, these amounts are considered variable consideration and the Company estimates its refund liability for each claim, as needed, and recognizes revenue net of such estimate.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain contracts, consideration can include periodic performance-based bonuses which can be awarded based on the Company’s performance under the specific contract. These performance-based bonuses are considered variable and may be constrained by the Company until there is not a risk of a significant reversal.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied the as-invoiced practical expedient or the variable consideration allocation exception to contracts with performance obligations that have an average remaining duration of less than a year.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For healthcare claims audit contracts, the Company may recognize revenue upon delivering its findings from claims audits, when sufficient reliable information is available to the Company for estimating the variable consideration earned based on an output metric that reasonably measures the Company's satisfaction of its performance obligation.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For eligibility-based or COB contracts, the Company recognizes revenue when insurance companies or other responsible parties have remitted payments to its clients.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain recovery contracts, revenue is recognized when the clients collect on amounts owed to them as a result of the Company’s services. For student loan recovery services, loan rehabilitation revenue is recognized when the rehabilitated loans are funded by clients. Bonuses are recognized upon receipt of official notification of bonus awards from customers.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For customer care / outsourced services, the Company recognizes revenues based on the volume of processed transactions or the quantity of labor hours provided.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in cash used in operating activities in the consolidated statements of cash flows. The Company determines the allowance for doubtful accounts by specific identification. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is consider remote. The allowance for doubtful accounts was $29 thousand and $0 at March 31, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers of our clients have the right to appeal claims audit findings and may pursue additional appeals if the initial appeal is found in favor of healthcare clients. For eligibility or COB contracts, insurance companies or other responsible parties may dispute the Company’s findings regarding our clients not being the primary payer of healthcare claims. Total estimated liability for appeals and disputes was $1.5 million as of March 31, 2022 and $1.2 million as of December 31, 2021. This represents the Company’s best estimate of the amount probable of being refunded to the Company’s healthcare clients. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that it does not have any material costs related to obtaining or fulfilling a contract that are recoverable and as such, these contract costs are generally expensed as incurred.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets were approximately $8.9 million and $8.1 million as of March 31, 2022 and December 31, 2021, respectively. Contract assets relate to the Company’s rights to consideration for services completed during the respective years, but not invoiced at the reporting date, and receipt of payment is conditional upon factors other than the passage of time. Contract assets primarily consist of commissions the Company estimates it has earned from completed claims audit findings submitted to healthcare clients. The increase in contract assets resulted from additional consideration earned for services provided to healthcare clients during the period, offset by invoiced amounts.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are recorded to accounts receivable when the Company's right to payment becomes unconditional, which is generally when healthcare providers have paid our clients. There was no impairment loss related to contract assets for the three months ended March 31, 2022.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities were $0.8 million and $0.6 million as of March 31, 2022 and December 31, 2021, respectively. The Company’s contract liabilities related to certain reimbursable costs due to a healthcare client.</span></div>
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27083000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31390000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	29000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1500000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1200000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8900000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8100000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	800000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	600000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3900000	USD
CY2022Q1	us-gaap	Line Of Credit LineOfCredit	19875000	USD
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	20000000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	404000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	427000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	19471000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	19573000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	613000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	489000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18858000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19084000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	375000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1000000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1500000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1500000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	15500000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	921000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	635000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	398000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3399000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	270000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3129000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.02
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69873000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54813000	shares
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	19875000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1445000	USD
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69873000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54813000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6926	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11983	shares

Files In Submission

Name	View Source	Status
0001550695-22-000033-index-headers.html	Edgar Link	pending
0001550695-22-000033-index.html	Edgar Link	pending
0001550695-22-000033.txt	Edgar Link	pending
0001550695-22-000033-xbrl.zip	Edgar Link	pending
ex033122311cert.htm	Edgar Link	pending
ex033122312cert.htm	Edgar Link	pending
ex033122321cert.htm	Edgar Link	pending
ex033122322cert.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pfmt-20220331.htm	Edgar Link	pending
pfmt-20220331.xsd	Edgar Link	pending
pfmt-20220331_cal.xml	Edgar Link	unprocessable
pfmt-20220331_def.xml	Edgar Link	unprocessable
pfmt-20220331_htm.xml	Edgar Link	completed
pfmt-20220331_lab.xml	Edgar Link	unprocessable
pfmt-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHLT
Performant Healthcare Inc Stock $phlt

2022 Q2 Form 10-Q Financial Statement

#000155069522000033 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHLT Performant Healthcare Inc Stock $phlt

2022 Q2 Form 10-Q Financial Statement

#000155069522000033 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHLT
Performant Healthcare Inc Stock $phlt